Ardea's gout candidate passes Phase IIb
This article was originally published in Scrip
Executive Summary
Ardea Bioscience's lead gout candidate RDEA594 met its primary endpoint in a Phase IIb monotherapy study for the treatment of hyperuricaemia in gout patients, show top-line results. The novel drug is also being tested in combination with the hyperuricaemia drug allopurinol in a Phase IIb trial, with results due in the third quarter of the year.